PEG-Linked IL-2 Conjugates for Treg Selectivity and Longer Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cytokine therapies, such as IL-2, face challenges with toxicity and short in vivo half-life, limiting their therapeutic efficacy in autoimmune diseases.
Innovation Solution
Development of IL-2 conjugates with unnatural amino acids that reduce receptor signaling potency to IL-2Rβγ, enhance IL-2Rα subunit recruitment, and incorporate water-soluble polymers like PEG to extend half-life and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type IL-2 is used for therapy, then Treg cell activation is achieved, but toxicity increases and half-life remains short
Solution Approach 1:
The patent applies local quality by selectively modifying specific amino acid positions in the IL-2 molecule (positions 35, 71, 76, or 89) to alter its interaction with different receptor subunits. The modifications are localized to specific regions of the IL-2 molecule that contact the IL-2Rβγ complex, thereby selectively reducing affinity for this receptor while preserving or enhancing interaction with the IL-2Rαβγ complex on Treg cells. This localized modification strategy allows differential binding properties without completely altering the overall molecular structure.
Solution Approach 2:
The patent employs parameter changes by substituting natural amino acids with unnatural amino acids containing specific functional groups (azido, alkyne, aldehyde, or ketone groups) at defined positions. These parameter changes in the molecular structure enable covalent attachment of conjugating moieties while simultaneously modifying the receptor binding characteristics. The functional group type and position are carefully selected to achieve the desired balance between reduced toxicity and maintained therapeutic activity.
2Reliability
If wild-type IL-2 is used for therapy, then Treg cell activation is achieved, but in vivo half-life remains short
Solution Approach 1:
The patent uses conjugating moieties as intermediaries to extend the half-life of IL-2 conjugates in vivo. These conjugating moieties, which are covalently attached to the modified IL-2 through unnatural amino acids, act as mediators that protect the cytokine from rapid clearance and degradation. The conjugating moieties can include polyethylene glycol (PEG) chains, proteins, or other polymers that increase the hydrodynamic radius and reduce renal filtration, thereby extending circulation time and half-life of the therapeutic agent.
Solution Approach 2:
The patent creates composite structures by combining modified IL-2 polypeptides with conjugating moieties through covalent bonding. The resulting IL-2 conjugate is a composite material that integrates the bioactive cytokine component with the half-life extending polymer or protein component. This composite structure leverages the specific biological activity of IL-2 while incorporating the stability and prolonged circulation characteristics of the conjugating moiety, achieving both therapeutic efficacy and extended duration of action.
3Adaptability or versatility
If IL-2 receptor signaling potency is reduced, then selectivity for Treg cells improves, but binding affinity to IL-2Rβγ must be decreased
Solution Approach 1:
The patent applies local quality by selectively modifying specific amino acid positions in the IL-2 molecule (positions 35, 71, 76, or 89) to alter its interaction with different receptor subunits. The modifications are localized to specific regions of the IL-2 molecule that contact the IL-2Rβγ complex, thereby selectively reducing affinity for this receptor while preserving or enhancing interaction with the IL-2Rαβγ complex on Treg cells. This localized modification strategy allows differential binding properties without completely altering the overall molecular structure.
Solution Approach 2:
The patent employs parameter changes by substituting natural amino acids with unnatural amino acids containing specific functional groups (azido, alkyne, aldehyde, or ketone groups) at defined positions. These parameter changes in the molecular structure enable covalent attachment of conjugating moieties while simultaneously modifying the receptor binding characteristics. The functional group type and position are carefully selected to achieve the desired balance between reduced toxicity and maintained therapeutic activity.
Data Source
AI summary
Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).